Clinical trial · Observational
Verification of Saliva MMP-1 as a Diagnostic Marker of Oral Cavity Cancer
Verification of Saliva MMP-1 as a Strong Diagnostic Marker of Oral Cavity Cancer
NCT05049408CI-TRIAL-00054137completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study is designed to measure salivary matrix metalloproteinase-1 (MMP-1) using the enzyme-linked immunosorbent assay (ELISA) we developed previously in patients with oral potentially malignant disorders (OPMD), oral squamous cell carcinoma (OSCC), and healthy participants. The purpose of this study is to evaluate the potential of the newly developed salivary MMP-1 ELISA as an adjunctive tool to aid in diagnosis of OSCC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Oral Squamous Cell Carcinoma | Oral Cavity Squamous Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MMP-1 Enzyme Linked Immunosorbent assay (ELISA) | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Group OSCC
- description
- Patients with Oral Squamous Cell Carcinoma (OSCC)
- interventionNames
- Diagnostic Test: MMP-1 Enzyme Linked Immunosorbent assay (ELISA)
- label
- Group OPMD
- description
- Patients with oral potentially malignant disorders (OPMD)
- interventionNames
- Diagnostic Test: MMP-1 Enzyme Linked Immunosorbent assay (ELISA)
- label
- Group HC
- description
- Healthy Control
- interventionNames
- Diagnostic Test: MMP-1 Enzyme Linked Immunosorbent assay (ELISA)
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Group OSCC: patients with lesions of OSCC * Group OPMD: patients with lesions of OPMD * Group HC: healthy subjects who are not suffering from any oral lesions and having behaviors of smoking, and/or betel nut chewing Exclusion Criteria: * Subjects having personal history of other cancers or severe diseases
References
Publications (1)
- RESULTChang YT, Chu LJ, Liu YC, Chen CJ, Wu SF, Chen CH, Chang IY, Wang JS, Wu TY, Dash S, Chiang WF, Chiu SF, Gou SB, Chien CY, Chang KP, Yu JS. Verification of Saliva Matrix Metalloproteinase-1 as a Strong Diagnostic Marker of Oral Cavity Cancer. Cancers (Basel). 2020 Aug 13;12(8):2273. doi: 10.3390/cancers12082273. PMID 32823758